AVR · Anteris Technologies Global Corp. · Stock research

Current Thesis

Clinical-stage structural-heart disruptor, dual-listed ASX/NASDAQ, whose DurAVR THV a single-piece, 3D-shaped biomimetic transcatheter aortic valve is enrolling the US-pivotal PARADIGM trial. The de-risking sequence that powered the multi-quarter run is now complete: CMS Coverage-with-Evidence-Development under NCD 20.32 (2026-04-28), first US patients treated at Montefiore (2026-05-05, Dr. Azeem Latib), and full French ANSM clearance (2026-06-08). Since that last milestone the tape has done the talking: price pushed to a fresh 52-week high near $11.06, then faded roughly 11% to $9.77 at the July 10 close (+2.95% on the day, $9.99 after-hours), settling back near the $9.00 TD Cowen ATM reference. That fade matters the leg to new highs was price-led with no fresh narrative fuel, and it ran straight into a live in-the-money $250M ATM seller. The real value inflection, PARADIGM's 1-year primary endpoint, sits ~2028 (enrollment completes ~Q1 2027). A genuine disruptor with a Strong-Buy sell-side and ~64% of upside to the $16 average target, but with no 30-day binary, a standing dilution shelf at these prices, a momentum leg that just stalled, and no peer cluster confirming. Maturing and idiosyncratic; a low-conviction watch, not a fresh-entry setup.

Bullish and bearish views on Anteris Technologies Global Corp.

The model's bull view on Anteris Technologies Global Corp. (AVR), in brief: Pivotal trial live and geographically broadening full French ANSM clearance (2026-06-08) opened recruitment at experienced French centers on top of active US and European sites; first US patients treated 2026-05-05 (Montefiore, Dr. Latib). The bear view: The $250M ATM is an in-the-money seller into the fade. Both cases follow in full.

Bull Case

• Pivotal trial live and geographically broadening full French ANSM clearance (2026-06-08) opened recruitment at experienced French centers on top of active US and European sites; first US patients treated 2026-05-05 (Montefiore, Dr. Latib). PARADIGM is ~1,000 patients, 1:1 randomized DurAVR vs commercial TAVR, non-inferiority composite (all-cause mortality + all stroke + CV hospitalization) at 1 year.
• Reimbursement de-risked early CMS Coverage-with-Evidence-Development under NCD 20.32 approved 2026-04-28; US site activation followed within a week, clearing the largest US trial-execution risk before enrollment scaled.
• Incumbent strategic validation Covidien (Medtronic subsidiary) committed up to $90M for 16–19.99% of post-offering shares, closed 2026-01-22 alongside a $230M public raise ($320M aggregate). An incumbent funding a competing valve is a real endorsement.
• Sell-side leaning in consensus reads Strong/Moderate Buy, average PT $16.00 (~64% above the $9.77 close); Barclays Overweight PT $18 (2026-05-15), Wells Fargo Overweight PT $16 (2026-03-11), Cantor Overweight PT $15 (2026-03-27).
• Balance sheet funded through enrollment January raise plus the $250M ATM facility cover the ~$28.7M/qtr burn with no near-term financing cliff; market cap ~$951M as of 2026-07-10.

Bear Case

• The $250M ATM is an in-the-money seller into the fade. TD Securities sales agreement dated 2026-05-22, up to $250M (~26M+ shares, ~27% of the ~97M count) at 3.0% commission. Above $9 the company can issue directly into strength the same facility manufactures supply at the level the chart is now retesting from above.
• Momentum leg stalled with no catalyst behind it. Price made a new high near $11.06, then gave back ~11% to $9.77 by 2026-07-10 on no news. CMS, first-patient, and French clearance are all done; each was an enrollment-pace step, not a data readout. The 1-year binary is ~2028 (enrollment completes ~Q1 2027).
• Pre-revenue with deep losses 2025 net loss $94.14M on $1.91M revenue (−29% YoY); Q1 2026 net cash outflow $28.7M ($17.5M to R&D), EPS $(0.28) missed by a penny, sales $494K vs $766.67K est.
• Not everyone is bullish Weiss Ratings reiterated Sell (D-) on 2026-05-29, the lone contrarian against four buy-side targets; any clinical hiccup on a pre-revenue name is binary downside.
• Single-name, no cluster TAVR peers (EW, MDT, BSX) are mega-caps not breaking out together; there is no small-cap disruptor cohort confirming the move. Strength here has been idiosyncratic.

Setup & Price Structure

The multi-month advance from the $2.85 52-week low extended to a fresh high near $11.06, then failed to hold it: price faded to ~$10.22 (2026-06-24) and on to $9.77 at the 2026-07-10 close, a ~11–12% pullback from the peak that lands it in the middle of its recent range and right at the $9.00 TD Cowen ATM reference. The July 10 session bounced +2.95% ($9.99 after-hours), so the pivot is being defended for now, but the structure is a stalled breakout digesting rather than an accelerating leg. The de-risking newsflow that drove prior legs is exhausted, and the next dated item (the ASX quarterly cash report) is a burn/dilution disclosure, not an upside readout. For a fresh position this is the awkward zone: not stretched enough to fade, not supported by a catalyst to chase, and sitting on a level the company itself can print stock into. Cleaner setups would be a decisive reclaim of $11+ on an actual clinical or enrollment-pace catalyst, or a deeper flush that resets sentiment near firmer support.

Catalyst Calendar (next 30 days)

• ~2026-07-31 (est.) ASX Appendix 4C quarterly activities & cash-flow report for the quarter ended 2026-06-30. Watch ATM-draw pace against the ~$28.7M/qtr Q1 burn; heavy issuance into the fade would confirm the dilution overhang.
• No clinical/data catalyst in the window CMS CED, first US patients, and French ANSM clearance are behind; PARADIGM enrollment completes ~Q1 2027, 1-year data ~2028. The push to new highs was price-led, not news-led.

Elapsed catalysts

• Beyond the window Q2 2026 US results print ~mid-August 2026 (Q1 reported 2026-05-12); avoid treating that as a directional binary given it is a cash-burn update, not a data readout. _(passed 68d ago)_

What Would Change Our Mind

The maturing read flips constructive on a decisive weekly reclaim of the $11.06 high paired with an actual enrollment-pace or clinical catalyst rather than pure momentum, or on the Appendix 4C showing restrained ATM draw and a slowing burn (removing the dilution-into-strength worry). It flips negative on a weekly close below $9.00, which puts price back under the reclaimed ATM reference and the dilution shelf; an 8-K or 4C disclosing heavy ATM issuance would confirm supply is being fed into the tape. Any PARADIGM enrollment halt or safety signal is a separate, structural break independent of price.

Correlation Notes

AVR trades on its own clinical newsflow, not as a TAVR-theme proxy. The listed peers Edwards Lifesciences (EW), Medtronic (MDT), Boston Scientific (BSX) are mega-cap incumbents whose tape does not lead or confirm AVR's moves, so beta to the structural-heart complex is low. Medtronic is a special case: it is both a strategic investor (Covidien, up to $90M / 16–19.99% post-offering) and the incumbent competitor DurAVR is trying to displace, a dual relationship worth tracking. The stock is dual-listed ASX:AVR / NASDAQ:AVR, and the ASX session typically leads the US tape, so the overnight Australian print is the tell for US-open direction. The dominant single-name driver is the $250M TD Cowen ATM: above $9 it is a live supply source that can cap rallies regardless of broad-market or sector risk appetite.

Correlation Notes (data anchors)

Market cap ~$951M (2026-07-10); float ~97M shares; ATM up to ~27% of count. Consensus PT $16.00 (range $15–$18), Strong/Moderate Buy, one Sell (Weiss, 2026-05-29).